Yi Shi is the Managing Partner of Lilly Asia Ventures, a venture capital fund affiliated with Eli Lilly and investing in the health care sector in Asia, particularly China.
Yi has been in the current role since the fund’s founding in 2008; prior to this he worked at Eli Lilly and Company with a diverse set of experiences including operations, marketing, business development licensing, and corporate strategy. Currently, he serves on the Board of HD Biosciences, Chipscreen Biosciences, Beta Pharma, BrightGene Biomedical, Novast Holdings, Sinqi Pharmaceuticals, CPC Scientific, and Innovent Biologics.
Yi’s education includes a Ph.D. in Biochemistry and an MBA degree, both from Duke University. He also earned a Bachelor of Sciences in Biology from the University of Science and Technology of China.